Menopause and mood.
C. Soares,H. Joffe,M. Steiner
DOI: https://doi.org/10.1097/01.GRF.0000129918.00756.D5
2004-09-01
Abstract:Introduction Data derived from the 2002 U.S. Census have shown an increase in the female population (around 146.7 million). Starting with 35 years old, women outnumbered men; at age 85 or older, there were more than twice as many women as men. The 2002 census suggest that around 1.5 million women will reach menopause each year in the U.S. The transition to menopause is frequently accompanied by significant physical and emotional changes such as vasomotor symptoms, sleep disruption, sexual dysfunction, mood disturbances, and cognitive difficulties. Community-based studies have also identified the transitioning to menopause as a period of heightened risk for some women to develop clinically significant depressive symptoms. The risk for a “perimenopausal depressive syndrome” appears to be significant even among those patients who have never experienced depression prior to the perimenopause. The presence of life stressors (e.g., lack of social support, unemployment), history of surgical menopause, and poor health conditions may contribute to or exacerbate such risk. Several studies support the efficacy of estrogen therapy (ET) to alleviate menopauserelated insomnia and vasomotor symptoms. In addition, growing clinical evidence suggests that ET may also promote improvement of depressive symptoms, psychosocial functioning, and quality of life. However, recent reports derived form the Women’s Health Initiative study (WHI) have questioned the safety of long-term use of ET; whereas estrogen (in combination with progestogens, for women with an intact uterus) was used previously for the treatment of vasomotor symptoms and as a prophylactic strategy for cardiovascular diseases and osteoporosis, the WHI findings have discredited its use for clinical indications other than management of vasomotor symptoms. Researchers, clinicians, and menopause societies have pointed out several limitations of the WHI findings (addressed in different articles in this issue); nonetheless, a large number of women have opted for discontinuing hormone therapy (HT). Others now transitioning to menopause are seeking for alternatives to avoid Correspondence: Claudio N. Soares MD, PhD, Center for Women’s Mental Health, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114. E-mail: csoares@partners.org CLINICAL OBSTETRICS AND GYNECOLOGY Volume 47, Number 3, 576–591 © 2004, Lippincott Williams & Wilkins